Levosalbutamol sulphate

For the use of a Registered Medical Practitioner or a Hospital or a Laboratory only LEVOLIN respules 0.31 mg Each 2.5 mL contains: Levosalbutamol Sulphate, IP Equivalent to Levosalbutamol…….. 0.31 mg In normal saline solution …………...q.s. LEVOLIN respules 0.63 mg Each 2.5 mL contains: Levosalbutamol Sulphate, IP Equivalent to Levosalbutamol…….. 0.63 mg In normal saline solution …………...........q.s. LEVOLIN respules 1.25 mg Each 2.5 mL contains: Levosalbutamol Sulphate, IP Equivalent to Levosalbutamol…….. 1.25 mg In normal saline solution …………...........q.s. LEVOLIN respules are supplied as a sterile, clear, colourless, aqueous solution for inhalation in a unit-dose, single-use LDPE respule. Each unit-dose respule of 2.5 mL is available in three dosage strengths of levosalbutamol – 0.31 mg, 0.63 mg, and 1.25 mg. Therapeutic Indications LEVOLIN respules are indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children (6 to 11 years old) with reversible obstructive airway disease. Posology and Method of Administration LEVOLIN respule contains Levosalbutamol inhalation solution. Levosalbutamol inhalation solution is for oral inhalation only. Administer by nebulisation using with a standard jet nebuliser (with a face mask or mouthpiece) connected to an air compressor. Do not exceed the recommended dose. Paediatric Patients (6 to 11 Years Old) : The recommended dosage of levosalbutamol inhalation solution, for patients 6–11 years old is 0.31 mg ad...

• • About Us • • • • • • • • Investor Relation • Corporate Governance • • Others • Safety • Corporate Social Responsibility • • Material Contracts and Documents for inspection • • • Updates & Announcements • • • • • Institutional Investor Meet • • • Shareholding Pattern • • Financial • • • • • • • • Operations • • • • • • • Contact • • • Levosalbutamol, or levalbuterol, is a short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). Salbutamol has been marketed as a racemic mixture, although beta2-agonist activity resides almost exclusively in the (R)-enantiomer. The enantioselective disposition of salbutamol and the possibility that (S)-salbutamol has adverse effects have led to the development of an enantiomerically pure (R)-salbutamol formulation known as levosalbutamol (levalbuterol).

OS(O)(=O)=O.CC(C)(C)NC[C@H](O)C1=CC(CO)=C(O)C=C1.CC(C)(C)NC[C@H](O)C1=CC(CO)=C(O)C=C1 External Links ChemSpider ChEMBL Predicted Properties Property Value Source Water Solubility 2.15 mg/mL logP 0.44 logP 0.34 logS -2 pKa (Strongest Acidic) 10.12 pKa (Strongest Basic) 9.4 Physiological Charge 1 Hydrogen Acceptor Count 4 Hydrogen Donor Count 4 Polar Surface Area 72.72 Å 2 Rotatable Bond Count 10 Refractivity 67.87 m 3·mol -1 Polarizability 26.86 Å 3 Number of Rings 2 Bioavailability 1 Rule of Five No Ghose Filter No Veber's Rule No MDDR-like Rule No

Usual Adult Dose for: • • Usual Pediatric Dose for: • • Additional dosage information: • • • • • • Usual Adult Dose for Chronic Obstructive Pulmonary Disease Inhalation Aerosol: • 2 inhalations (90 mcg) orally every 4 to 6 hours or • 1 inhalation (45 mcg) orally every 4 hours Inhalation Solution: • Initial dose: 0.63 mg inhaled orally by nebulization three times a day (every 6 to 8 hours) • For severe asthma, or if not responding to initial dose: 1.25 mg inhaled orally, by nebulization, three times a day Comments: • If higher doses of the inhalation solution are used, monitor closely for adverse systemic effects; evaluate risk and benefit of this dose. • If a previously effective dosage fails to provide the usual response, it may be a sign of destabilization of asthma; reevaluate the patient and treatment and consider the use of corticosteroids. • The safety and efficacy of the inhalation solution has not been evaluated when mixed together with other drugs in a nebulizer. Uses: Treatment or prevention of bronchospasm in patients with reversible obstructive airway disease; asthma Usual Adult Dose for Asthma Inhalation Aerosol: • 2 inhalations (90 mcg) orally every 4 to 6 hours or • 1 inhalation (45 mcg) orally every 4 hours Inhalation Solution: • Initial dose: 0.63 mg inhaled orally by nebulization three times a day (every 6 to 8 hours) • For severe asthma, or if not responding to initial dose: 1.25 mg inhaled orally, by nebulization, three times a day Comments: • If higher...

For the Use of Registered Medical Practitioner or a Hospital or a Laboratory only A clear, colourless solution in a clear low-density polyethylene (LDPE) respule. Each 2.5 ml unit-dose respule contains: Levosalbutamol Sulphate IP……………….0.63 mg Ipratropium Bromide IP equivalent to Ipratropium bromide (anhydrous)……………....………………….500 mcg Isotonic Saline Solution, IP …………….....q.s. DUOLIN LD respule is supplied as a unit-dose vial of 2.5mL sterile solution for nebulization. Therapeutic Indication DUOLIN LD respule is indicated for the treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD) in patients requiring more than one bronchodilator. Posology and Method of Administration Children 6 to 11 years old: Dosing should not exceed three times a day. Adults and Adolescents ≥ 12 years old: Administered three times a day, every 6 to 8 hours, by nebulization. DUOLIN LD respule is for oral inhalation only. Administer by nebulization using with a standard jet nebulizer (with a face mask or mouthpiece) connected to an air compressor. Do not exceed recommended dose. Contraindications DUOLIN LD respule is contraindicated in patients with a history of hypersensitivity to any of its components, or to atropine and its derivatives. Reactions have included urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema. Special Warnings and Precautions for Use Levosalbutamol sulfate Paradoxical Bronchospasm Levosalbutamol inhalation solution can...

Levalbuterol (Levosalbutamol) + Ambroxol + Guaifenesin is a prescription medicine. It is typically used for the treatment of Cough, Common Cold. The alternative uses of Levalbuterol (Levosalbutamol) + Ambroxol + Guaifenesin have also been explained below. Medical history of the patient along with age and gender determines the dosage of Levalbuterol (Levosalbutamol) + Ambroxol + Guaifenesin. Dosage also depends on the route of administration and your chief complaint for which the drug is prescribed. Detailed information has been provided in the dosage section. The side effects typically associated with Levalbuterol (Levosalbutamol) + Ambroxol + Guaifenesin include Nausea or vomiting, Dizziness, Stomach Upset. Besides the aforementioned side effects, there are other adverse effects of Levalbuterol (Levosalbutamol) + Ambroxol + Guaifenesin as well, which are listed below. Such side effects of Levalbuterol (Levosalbutamol) + Ambroxol + Guaifenesin normally do not last long and go away once the treatment is completed. If, however, they worsen or do not go away, please speak with your physician. Levalbuterol (Levosalbutamol) + Ambroxol + Guaifenesin's effect during pregnancy is Moderate and Unknown while nursing. It is important to know if Levalbuterol (Levosalbutamol) + Ambroxol + Guaifenesin has any effect on the kidney, liver and heart. Information on such adverse effects, if any, has been given in the Levalbuterol (Levosalbutamol) + Ambroxol + Guaifenesin related warnings se...

For the Use of Registered Medical Practitioner or a Hospital or a Laboratory only A clear, colourless solution in a clear low-density polyethylene (LDPE) respule. Each 2.5 ml unit-dose respule contains: Levosalbutamol Sulphate IP……………….0.63 mg Ipratropium Bromide IP equivalent to Ipratropium bromide (anhydrous)……………....………………….500 mcg Isotonic Saline Solution, IP …………….....q.s. DUOLIN LD respule is supplied as a unit-dose vial of 2.5mL sterile solution for nebulization. Therapeutic Indication DUOLIN LD respule is indicated for the treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD) in patients requiring more than one bronchodilator. Posology and Method of Administration Children 6 to 11 years old: Dosing should not exceed three times a day. Adults and Adolescents ≥ 12 years old: Administered three times a day, every 6 to 8 hours, by nebulization. DUOLIN LD respule is for oral inhalation only. Administer by nebulization using with a standard jet nebulizer (with a face mask or mouthpiece) connected to an air compressor. Do not exceed recommended dose. Contraindications DUOLIN LD respule is contraindicated in patients with a history of hypersensitivity to any of its components, or to atropine and its derivatives. Reactions have included urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema. Special Warnings and Precautions for Use Levosalbutamol sulfate Paradoxical Bronchospasm Levosalbutamol inhalation solution can...

Usual Adult Dose for: • • Usual Pediatric Dose for: • • Additional dosage information: • • • • • • Usual Adult Dose for Chronic Obstructive Pulmonary Disease Inhalation Aerosol: • 2 inhalations (90 mcg) orally every 4 to 6 hours or • 1 inhalation (45 mcg) orally every 4 hours Inhalation Solution: • Initial dose: 0.63 mg inhaled orally by nebulization three times a day (every 6 to 8 hours) • For severe asthma, or if not responding to initial dose: 1.25 mg inhaled orally, by nebulization, three times a day Comments: • If higher doses of the inhalation solution are used, monitor closely for adverse systemic effects; evaluate risk and benefit of this dose. • If a previously effective dosage fails to provide the usual response, it may be a sign of destabilization of asthma; reevaluate the patient and treatment and consider the use of corticosteroids. • The safety and efficacy of the inhalation solution has not been evaluated when mixed together with other drugs in a nebulizer. Uses: Treatment or prevention of bronchospasm in patients with reversible obstructive airway disease; asthma Usual Adult Dose for Asthma Inhalation Aerosol: • 2 inhalations (90 mcg) orally every 4 to 6 hours or • 1 inhalation (45 mcg) orally every 4 hours Inhalation Solution: • Initial dose: 0.63 mg inhaled orally by nebulization three times a day (every 6 to 8 hours) • For severe asthma, or if not responding to initial dose: 1.25 mg inhaled orally, by nebulization, three times a day Comments: • If higher...

Levalbuterol (Levosalbutamol) + Ambroxol + Guaifenesin is a prescription medicine. It is typically used for the treatment of Cough, Common Cold. The alternative uses of Levalbuterol (Levosalbutamol) + Ambroxol + Guaifenesin have also been explained below. Medical history of the patient along with age and gender determines the dosage of Levalbuterol (Levosalbutamol) + Ambroxol + Guaifenesin. Dosage also depends on the route of administration and your chief complaint for which the drug is prescribed. Detailed information has been provided in the dosage section. The side effects typically associated with Levalbuterol (Levosalbutamol) + Ambroxol + Guaifenesin include Nausea or vomiting, Dizziness, Stomach Upset. Besides the aforementioned side effects, there are other adverse effects of Levalbuterol (Levosalbutamol) + Ambroxol + Guaifenesin as well, which are listed below. Such side effects of Levalbuterol (Levosalbutamol) + Ambroxol + Guaifenesin normally do not last long and go away once the treatment is completed. If, however, they worsen or do not go away, please speak with your physician. Levalbuterol (Levosalbutamol) + Ambroxol + Guaifenesin's effect during pregnancy is Moderate and Unknown while nursing. It is important to know if Levalbuterol (Levosalbutamol) + Ambroxol + Guaifenesin has any effect on the kidney, liver and heart. Information on such adverse effects, if any, has been given in the Levalbuterol (Levosalbutamol) + Ambroxol + Guaifenesin related warnings se...

• • About Us • • • • • • • • Investor Relation • Corporate Governance • • Others • Safety • Corporate Social Responsibility • • Material Contracts and Documents for inspection • • • Updates & Announcements • • • • • Institutional Investor Meet • • • Shareholding Pattern • • Financial • • • • • • • • Operations • • • • • • • Contact • • • Levosalbutamol, or levalbuterol, is a short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). Salbutamol has been marketed as a racemic mixture, although beta2-agonist activity resides almost exclusively in the (R)-enantiomer. The enantioselective disposition of salbutamol and the possibility that (S)-salbutamol has adverse effects have led to the development of an enantiomerically pure (R)-salbutamol formulation known as levosalbutamol (levalbuterol).